Crossmark

Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis

Crossref DOI link: https://doi.org/10.1007/s12325-019-0887-1

Published Online: 2019-02-07

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Zuojun

Li, Huiping

Wen, Fuqiang

Bai, Chunxue

Chen, Ping

Fan, Feng

Hu, Na

Stowasser, Susanne

Kang, Jian
Funding

Funding for this research was provided by:

Boehringer Ingelheim
License Information

Text and Data Mining valid from 2019-02-07
More Information

Article History

Received: 6 November 2018

First Online: 7 February 2019